#139

Pricing in Mexico is now below US $1500 per 30 x 0.5mg Trametinib (Resultado de tu búsqueda: 1 resultado relacionados a "Mekinist 0.5mg" – Farmacia Santa Rita), so under $50 per tablet. Due to the high cost most smaller pharmacies won’t carry it but larger pharmacies will deliver to any smaller pharmacy in Mexico for pickup, so those living on the US border to Mexico might be able to get it for a reasonable price, without worrying about refrigeration or customs impoundment. Since the dosage would be 0.5mg every 20 days, that is around $2.5/day.

1 Like
#140

This line of mouse is bred for sensitivity to carcinogens and trametinib is a kinase inhibitor. How much of the longevity outcome is accounted for along those lines of effect?

1 Like
#141

This research group saw the same benefits from the combination of drugs in their earlier studies with drosophila, so that doesn’t seem very relevant.

3 Likes
#142

Probably not and I get it but the drop off of relevance between flies, mice, and men is a really steep curve. As of today, there is no randomized controlled research demonstrating that rapamycin causes a longer life, or much of anything passing a risk/benefit analysis.

There are five experimental trials underway with the following endpoints and stages:

  1. PEARL Study
    Endpoints:
    Primary: Changes in biomarkers of aging, such as epigenetic age, immune function, and inflammatory markers (e.g., CRP, IL-6).
    Secondary: Self-reported measures of physical and cognitive function, frailty, and quality of life.
    Stage: Completed (results pending publication).
  2. Vibrant Study
    Endpoints:
    Primary: Effects of rapamycin on ovarian reserve markers (e.g., Anti-Müllerian Hormone [AMH] levels, follicle count).
    Secondary: Impact on menstrual cycle regularity, energy levels, and subjective well-being.
    Stage: Ongoing (participant recruitment and preliminary data collection).
  3. Rapamycin and Exercise in Older Adults with Coronary Artery Disease (CAD)
    Endpoints:
    Primary: Improvements in physical performance metrics (e.g., VO₂ max, muscle strength).
    Secondary: Changes in aging biomarkers, inflammation levels, and endothelial function.
    Stage: Recruitment phase.
  4. Rapamycin in Periodontal Disease Prevention
    Endpoints:
    Primary: Reduction in periodontal pocket depth and inflammation markers in gum tissue.
    Secondary: Impact on systemic inflammatory markers and oral microbiota composition.
    Stage: Early stage (initial safety and efficacy evaluation).
  5. Rapamycin Effects on Muscle and Bone Aging
    Endpoints:
    Primary: Preservation of muscle mass and bone density measured through DEXA scans and muscle strength tests.
    Secondary: Changes in mitochondrial function, markers of oxidative stress, and incidence of frailty.
    Stage: Ongoing (data collection phase).